Metraipolis › archive › dc_af4a2da3d575

The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental… — Europe PMC PMID:41009577

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41009577
DOI
10.3390/ijms26189010
License (as archived)
solo-consultazione
Archived
2026-11-09T22:21:24.900Z
SHA-256 of the archived text
a520a1fca55fad83fe372a78f952ad235cc57b40328fc3f63f1d2ef9635e98a1
Stable URL of this page
https://metraipolis.com/documento/dc_af4a2da3d575

How to cite

The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental… — Europe PMC PMID:41009577 — Europe PMC (en), https://europepmc.org/article/MED/41009577 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_af4a2da3d575 (Metraipolis archive dc_af4a2da3d575, sha256 a520a1fca55fad83fe372a78f952ad235cc57b40328fc3f63f1d2ef9635e98a1)
BibTeX
@misc{dcaf4a2da3d575,
  title = {The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental… — Europe PMC PMID:41009577},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41009577},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_af4a2da3d575; sha256 a520a1fca55fad83fe372a78f952ad235cc57b40328fc3f63f1d2ef9635e98a1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41009577. Agents can read the archived copy with the MCP tool read_document.